Equities

Alphamab Oncology

Alphamab Oncology

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.13
  • Today's Change0.26 / 6.72%
  • Shares traded15.91m
  • 1 Year change-67.48%
  • Beta1.8566
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
OPERATIONS
Net income(211)(326)(412)
Depreciation/depletion695541
Non-Cash items(69)(69)13
Cash taxes paid, supplemental------
Cash interest paid, supplemental111915
Changes in working capital8.014037
Total cash from operations(203)(300)(321)
INVESTING
Capital expenditures(36)(130)(158)
Other investing and cash flow items, total18980732
Total cash from investing(18)851574
FINANCING
Financing cash flow items(15)(19)(15)
Total cash dividends paid------
Issuance (retirement) of stock, net3210.250.35
Issuance (retirement) of debt, net(88)(292)378
Total cash from financing218(311)364
NET CHANGE IN CASH
Foreign exchange effects20260.42
Net change in cash17266618
Net cash-begin balance/reserved for future use1,069803185
Net cash-end balance/reserved for future use1,0861,069803
SUPPLEMENTAL INCOME
Depreciation, supplemental695541
Cash interest paid, supplemental111915
Cash taxes paid, supplemental------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.